Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Nanobiotech in the U.S.
FDA’s recently enacted budget for this fiscal year included some good news for proponents of nanotechnology as well as the promise for more in the years ahead. The agency’s National Center for Toxicological Research (NCTR), which conducts research on new medical products like nanomaterials, was approved $60 million for fiscal 2012, flat compared to FY ’11. Sen. Mark Pryor (D-AR) also inserted language in the House-Senate conference report endorsing the development of a nanotechnology core facility. One such site became operational last fiscal year, the other is set for FY 2012. These are among efforts to maintain U.S. leadership in nanotech. Europe is the nearest-term threat, but China, Singapore, and Taiwan are among others. What are your predictions?